The Syrian hamster embryo (SHE) cell-transformation assay represents a short-term in vitro assay capable of predicting rodent carcinogenicity of chemicals with a high degree of concordance (LeBoeuf et al [1996]. Mutat Res 356: 85-127). The SHE assay models the earliest identi able stage in carcinogenicity, morphological cell transformation. In contrast to other short-term in vitro assays, both genotoxic and epigenetic carcinogens are detected. The SHE assay, originally developed by Berwald and Sachs (J Natl Cancer Inst 35: 641-661) and modi ed as described by Kerckaert (Carcinogenesis 7: 1431-1440), was included in the International Life Sciences Institute, Health and Environmental Sciences Institute (ILSI/HESI). Alternative Carcinogenicity Testing (ACT) collaboration to provide additional information on the use of short-term in vitro tests in predicting carcinogenic potential. A total of 19 ILSI compounds have been tested in the SHE assay: 15 were tested for this project, whereas clo brate, methapyrilene, reserpine, and Di(2-ethylhexyl)phalate (DEHP) were tested previously. Of the 3 noncarcinogenic compounds tested, 2 were negative in the SHE assay, whereas ampicillin was tested positive. The remaining 16 compounds tested were either known rodent carcinogens and/or human carcinogens. From this group, 15 tested positive in the SHE assay whereas phenacetin, a genotoxic carcinogen, was tested negative. Therefore, overall concordance between the SHE assay and rodent bioassay was 89% (17/19), whereas concordance with known or predicted human carcinogens was 37% (7/19). Based on these data, it is concluded that the SHE cell-transformation assay has utility for predicting the results of the rodent carcinogenesis bioassay but lacks the selectivity to distinguish between rodent and human carcinogens.
INTRODUCTION
Syrian hamster embryo (SHE) cells have been used extensively to study the process of in vitro cell transformation (2) and have been proposed as a useful model system to assess the potential carcinogenicity of diverse chemicals (4, 5) . In contrast to most in vitro assays that measure the capacity of a compound to induce a very speci c event, such as mutations or chromosomal aberrations, the SHE assay uses a transformed phenotype as the endpoint. Because cancer is recognized as a multistep process, with many possible mechanisms leading to the ultimate transforming event, the use of a more general endpoint, such as the transformation of cells in vitro, may be of high predictive value. LeBoeuf et al (1) have demonstrated that SHE cells, when cultured in an environment of reduced bicarbonate (low pH), will morphologically transform at a rate high enough to allow for rigorous statistical evaluation. SHE cells, which can be cryopreserved (6, 7) , maintain a competent metabolic system to activate procarcinogenic agents to their carcinogenic forms, which eliminates the need for the addition of exogenous metabolic activation systems as typically required for in vitro assays (4, 5) . The transformed phenotype of the SHE cells has also been associated with increased neoplastic potential and the morphological endpoint can be determined in 7 to 9 days (8, 9) . The SHE assay was included in the International Life Sciences Institute Health and Environmental Sciences Institute Alternative Carcinogenicity Testing (ACT) program as a promising in vitro assay to predict rodent and human carcinogenesis. For this comparison, results are reported for 19 of the 21 ILSI compounds evaluated for the ability to induce cell transformation.
MATERIALS AND METHODS Chemicals
The chemicals used in this study, along with their CAS numbers, source, and the sponsor responsible for the conducting of the assay are listed in Table 1 . The suppliers included Sigma Chemical Company (St. Louis, MO), RWJ Pharmaceutical Research Institute, Janssen Pharmaceutica (Belgium), Lancaster Synthesis (Windham, NJ), Solvay Pharmaceuticals (Hannover, Germany), and Spectrum Quality Products (Gardenia, CA). All chemicals were of the highest purity available. The classi cation of the chemicals as genotoxic human carcinogens, immunosuppresent human carcinogens, hormones, rodent carcinogens/putative human noncarcinogens, and noncarcinogens was determined by the ILSI ACT group. In all experiments, benzo[a]pyrene (B[a]P; CAS #50-32-8; Sigma) was used as a positive control.
Culture Medium
Complete culture medium was prepared by adding 128 ml of fetal bovine serum (FBS) (Hyclone Inc., Logan, Utah), 
Solubility and Test Article Handling
Preliminary solubility experiments were typically performed to determine the most appropriate solvent for the test article. The order of preference for solvents is culture medium, DMSO, ethanol, and acetone. Stock solutions prepared with organic solvents were diluted 500-fold into complete culture medium, resulting in a nal solvent concentration of 0.2% v/v or less.
Preliminary Cytotoxicity Assay
The preliminary cytotoxicity and de nitive SHE assays were conducted using methods recently summarized by Custer et al (10) . A cytotoxicity experiment was conducted, prior to the transformation assay, to establish the appropriate dose range for testing. Cryopreserved SHE cells were thawed and grown in asks for 2 to 4 days prior to use. Feeder cells were x-irradiated suf ciently to inhibit replication, but remain viable. Viability and the inhibition of replication was determined by seeding 5 feeder cell-only dishes. No colonies formed on these dishes; but viable attached feeder cells were present. For each treatment group up to 10 60-mm Petri dishes were seeded with about 4 10 4 x-irradiated feeder cells in approximately 2 ml of complete culture medium. Target cells (1-2 10 6 ) were thawed, suspended in 10 ml culture medium, and centrifuged. The cell pellet was suspended in 5 ml warm culture medium, placed in a T-25 ask, and grown to subcon uency.
After approximately 24 hours, SHE target cells were seeded into dishes containing feeder cells seeded the previous day. The number of target cells seeded was calculated to produce 25 to 45 colonies per dish in the vehicle control. Suf cient target cells, in 2 ml of complete culture medium, were added to dishes already containing feeder cells, such that the nal volume was 4 ml. The cultures were then incubated at approximately 37 C with 10% CO 2 in humidi ed air for approximately 24 hours.
Test article dosing solutions were prepared fresh in complete culture medium at twice the desired nal concentration. Treatment consisted of delivering 4 ml of the 2 dosing stock to up to 10 dishes per treatment group (each containing 4 ml of complete medium, feeder and target cells). Cultures were incubated for approximately 24 hours, at which time the treatment medium was removed (for the 24-hour exposure). In the case of the 7-day exposure, the plates were incubated undisturbed for 7 to 8 days post treatment. The cultures were refed with 8 ml of fresh complete culture medium and were returned to the incubator for a period of 7 to 8 days.
After the incubation period, the dishes were washed once with Hank's balanced salt solution (HBSS), the colonies xed with methanol, stained with about 10% buffered aqueous Giemsa, rinsed in tap water, and air dried. The number of colonies per dish and plating ef ciency were then determined. The relative cytotoxicity for each treatment group was measured by reduction of relative plating ef ciency (RPE, calculated by comparing the plating ef ciency of treated groups to the vehicle control) and utilized to select doses for use in the de nitive SHE transformation assay.
SHE Transformation Assay
The de nitive transformation assays were performed in an analogous manner to the preliminary cytotoxicity assay. Each experiment typically consisted of 20 to 40 culture dishes per treatment group, including at least 1 vehicle control and 1 concentration of benzo[a]pyrene. The target SHE cells, in clonal growth, were exposed to at least 3 concentrations of the test article. Dose levels were chosen based on cytotoxicity experiments conducted prior to the transformation assay. The highest concentration included was that which resulted in > 50% cytotoxicity, insolubility in the culture medium, or a maximum of 5 mg/ml. The lowest concentration tested was that which resulted in minimal effect when compared to the solvent control. Treatment groups with an RPE of less than 70% from the preliminary cytotoxicity assessment were identi ed as requiring target cell adjustment in order to maintain an average of 35 10 colonies per dish. The equalization was accomplished by increasing the number of target cells seeded relative to controls, by dividing the target cell seeding density by the percent RPE observed (or estimated) for those treatment groups. Cultures were dosed with the test article for a 24-hour exposure period then refed with LeBoeuf's modi ed DMEM and left undisturbed for a 7-day clonal expression period, or exposed to the test article for the entire 7-day period. After the incubation period, dishes were xed and stained as previously described for the preliminary range-nding assay. The total number of colonies per dish was counted and the stained dishes were screened for morphologically transformed colonies using a stereomicroscope. The criteria for de ning morphological transformation are piled up cells (both at the center and perimeter of the colony), extensive random-oriented three-dimensional growth, crisscrossing cells with increased cytoplasmic basophilia at the perimeter of the colony, and cells with decreased cytoplasm/nucleus ratios relative to normal cells.
For each treatment group the following was calculated: plating ef ciency (PE) (number colonies/dish number of cells seeded) 100, relative plating ef ciency (RPE) test group plating ef ciency divided by solvent control plating ef ciency, and morphologically transformed frequency (MTF) (number of MT colonies total number of colonies) 100.
The total colony number and the number of colonies with transformed morphology for each test group were recorded. Based on these data, plating ef ciencies and transformation frequencies were calculated. The assay data was then analyzed for statistically signi cant treatment-related effects using pooled data from the combined experiments. A chemical was predicted to be a carcinogen if it was positive in either a 24-hour or 7-day exposure. Note: If a chemical was positive under the 24-hour conditions, the assay was considered positive overall and therefore it was not considered necessary to test under the 7-day conditions in this case.
Criteria for an Acceptable Study
A study was considered valid if the B[a]P positive control caused a statistically signi cant increase in MTF from the negative control. The highest analyzed dose group was expected to cause at least a 50% reduction in relative plating ef ciency, unless the maximal soluble dose was used and no toxicity occurred or the number of cells/colony precluded scoring that dose level. Although not a strict criteria, efforts were made to maintain an RPE > 25% for all treatment groups with 25 to 45 colonies/dish and a total of 1000 colonies/treatment.
Statistical tests for signi cant treatment-related effects were employed using pooled data to evaluate the response to the test material. A test material was considered to be positive if it caused a statistically signi cant increase in morphological transformation frequency in at least 2 doses compared to concurrent controls. In addition, a test material was considered positive if 1 dose showed a statistically signicant treatment-related increase in MTF and an indication of a statistically signi cant ( p < 0.05) positive dose-response trend. A compound is concluded to be positive in the SHE assay if it is positive in either a 24-hour or 7-day exposure. To be judged negative in the SHE assay, a compound must be negative in both the 24-hour and 7-day exposures. A test material was considered negative if there was no dose with a statistically signi cant treatment-related increase and the uppermost dose of test material demonstrated a suf cient level of toxicity (i.e., either a 50% reduction in plating ef ciency or a colony density that precluded scoring at a higher concentration), unless no toxicity was observed at the maximum soluble dose.
Statistical Analysis
Statistical tests for signi cant treatment related effects on transformation frequencies were performed using a one-sided Fisher's Exact Test (11) . In this test the transformation frequency of the solvent control group was compared pairwise to the transformation frequencies of each test material group, including the positive B[a]P control group. When only 1 dose level was positive, an unstrati ed binomial exact permutation trend test for a signi cant positive dose-response trend was also conducted.
RESULTS

Genotoxic Human Carcinogens
Cyclophosphamide. With a 24-hour exposure, cyclophosphamide (in DMSO) was tested up to 2500 l g/ml (48% RPE) and caused a signi cant increase in MTF at 1500, 2000, and 2500 l g/ml. Cyclophosphamide was not tested with a 7-day exposure. Overall, cyclophosphamide was positive in the SHE assay.
Melphalan. With a 24-hour exposure, concentrations of melphalan (in culture media) up to 0.4 l g/ml (48% RPE) were tested. Melphalan caused a statistically signi cant increase in MTF compared with the solvent control at 0.28 and 0.35 l g/ml, indicating a positive result. Melphalan was not tested with a 7-day exposure. Overall, melphalan was positive in the SHE assay.
Phenacetin. Phenacetin was tested up to 500 l g/ml (in DMSO); concentration levels above 500 l g/ml were unscorable due to insolubility. The 500-l g/ml dose did not produce signi cant cytotoxicity. No signi cant increases in MTF were observed. With a 7-day exposure, phenacetin was tested up to an insoluble dose of 450 l g/ml with no evidence of cytotoxicity. No signi cant increases in MTF were observed. Overall, phenacetin was negative in the SHE assay.
Immunosuppressant Human Carcinogen
Cyclosporin A. With a 24-hour exposure, cyclosporin A (in DMSO) was tested up to 125 l g/ml with no evidence of cytotoxicity. Cyclosporin A caused a statistically signi cant increase in MTF at all concentrations 62.5 l g/ml. Cyclosporin A was not tested with a 7-day exposure. Overall, cyclosporin A was positive in the SHE assay.
Hormones
Diethylstilbestrol. Diethylstilbestrol (in DMSO) was tested up to 10 l g/ml, with signi cant toxicity (24% RPE) and caused a statistically signi cant increase in MTF at all concentrations 7.5 l g/ml. Diethylstilbestrol was not tested with a 7-day exposure. Overall, diethylstilbestrol was positive in the SHE assay.
Estradiol. With a 24-hour exposure, estradiol (in DMSO) was tested up to 15 l g/ml (31% RPE). Estradiol caused statistically signi cant increase in MTF at 7.5, 10, and 15 l g/ml. Estradiol was not tested with a 7-day exposure. Overall, estradiol was positive in the SHE assay.
Rodent Carcinogens/Putative Human Noncarcinogens-Based on Epidemiology
Phenobarbital. Phenobarbitol (in culture media) was tested up to 1200 l g/ml (52% RPE) and caused a statistically signi cant increase in MTF at all concentrations > 700 l g/ml. In this set of testing, phenobarbitol was not tested with a 7-day exposure; although previous testing with both 24-hour and 7-day exposures both produced positive results (1) . Overall, phenobarbitol was positive in the SHE assay.
Clo brate. Clo brate was not assessed in this set of testing; however, previous testing found it to be positive under both 24-hour and 7-day exposure conditions (1) .
Reserpine. Reserpine was not assessed in this set of testing; however, previous testing found it to be positive under both 24-hour and 7-day exposure conditions (1) .
Dieldrin. With a 24-hour exposure, dieldrin (in DMSO) was tested up to 18 l g/ml, with no signi cant effect on cytotoxicity. Dieldrin caused a statistically signi cant increase in MTF at all concentrations tested. No 7-day exposure was conducted with dieldrin. Overall, dieldrin was positive in the SHE assay.
Methapyrilene. Methapyrilene was not assessed in this set of testing; however, previous testing found it be negative with a 24-hour exposure, but positive with a 7-day exposure conditions and therefore positive in the SHE assay overall (1).
Rodent Carcinogens/Putative Human Noncarcinogens-Based on Mechanism
Haloperidol. Haloperidol (in DMSO) was tested at concentrations up to 50 l g/ml, with signi cant toxicity (36% RPE) with a 24-hour exposure. Haloperidol caused a statistically signi cant increase in MTF at 30 and 50 l g/ml and also caused a statistically signi cant positive dose-response trend. No 7-day exposure was conducted with haloperidol. Overall, haloperidol was positive in the SHE assay.
Chlorpromazine. With a 24-hour exposure, chlorpromazine was dissolved in culture media and was tested up to 20 l g/ml with signi cant cytotoxicity (48% RPE). Chlorpromazine caused a statistically signi cant increase in MTF at all concentrations 8 l g/ml. No 7-day exposure was conducted with chlorpromazine. Overall, chlorpromazine was positive in the SHE assay.
WY-14643. WY-14643 (in culture media) was tested at concentrations up to 50 l g/ml, with no signi cant effect on cytotoxicity with a 7-day exposure. WY-14643 caused a statistically signi cant increase in MTF at all concentrations tested. No 24-hour exposure was conducted with WY-14643 in this set of testing; however, previous testing found it be positive under both 24-hour and 7-day exposure conditions (1) . Overall, WY-14643 was positive in the SHE assay.
Di(2-ethylhexyl)phalate (DEHP). DEHP was not assessed in this set of testing; however, previous testing found it be negative when tested up to 5000 l g/ml under 24-hour exposure conditions, but positive with a 7-day exposure condition and therefore positive in the SHE assay overall (1). Sulfamethoxazole. With a 24-hour exposure, sulfamethoxazole was dissolved in DMSO and then tested up to 2000 l g/ml with evidence of cytotoxicity (61% RPE). Sulfamethoxazole caused a statistically signi cant increase in MTF at 1000 and 1250 l g/ml. Sulfamethoxazole was not tested with a 7-day exposure. Overall, sulfamethoxazole was positive in the SHE assay.
Noncarcinogens
Ampicillin. With a 24-hour exposure, ampicillin (in culture media) was tested up to 3000 l g/ml with evidence of cytotoxicity (60% RPE). Ampicillin induced a statistically signi cant increase in MTF at 3000 l g/ml and also caused a statistically signi cant positive dose-response trend. With a 7-day treatment, ampicillin was tested up to 1000 l g/ml with evidence of cytotoxicity (55% RPE). No statistically signicant increase in MTF was observed. Overall, ampicillin was positive in the SHE assay. D-Mannitol. D-mannitol (in culture media) was tested up to 5000 l g/ml under both 24-hour and 7-day exposure conditions, with no evidence of cytotoxicity. No statistically significant increase in MTF was observed in any of the experiments performed with mannitol with either this set of testing or previous testing (1) . Overall D-mannitol was negative in the SHE assay. Sul soxazole. With a 24-hour exposure, sul soxazole (in DMSO) was tested over a broad dose range of 25 to 1000 l g/ml, with a dose-dependent increase in cytotoxicity (93%-54% RPE). No statistically signi cant increase in MTF was observed. With a 7-day exposure, sul soxazole was tested up to 480 l g/ml (43% RPE) and failed to cause a statistically signi cant increase in MTF. Overall, sul soxazole was negative in the SHE assay.
DISCUSSION/CONCLUSION
Overall comparisons of the SHE cell-transformation assay to rodent carcinogenesis and known or predicted human carcinogenesis and the corresponding predicitivity of the SHE assay for these carcinogenicity endpoints are shown in Tables 2 and 3, respectively. Data tables on the individual compounds are provided in Table 4 . The overall concordance of the SHE assay with rodent bioassays of 89% (17/19) is consistent with previous reports (1) . When comparing to rodent bioassays, the SHE assay is highly sensitive, with positive SHE results observed for all 16 known rodent carcinogens, with the exception of phenacetin. The SHE assay was also speci c, determining the noncarcinogens mannitol and sul soxazole to be negative, but incorrectly identifying ampicillin as positive in SHE assay with a 24-hour exposure. Interestingly, the SHE assay correctly predicted the structurally similar, but carcinogenically distinct, compounds sul soxazole and sulfamethoxazole. Likewise, appropriate identi cation of organ-, species-, or gender-speci c carcinogens (e.g., dieldrin and chlorpromazine) and mechanismbased carcinogens (e.g, estradiol, diethylstilbestrol, and cyclosporin A) may be the result of utilizing primary cells, which comprise a wide variety of cell types and may be susceptible to various transformation pathways.
When compared to the known or predicted human carcinogenesis information, the overall concordance of the assay is reduced to 39% (7/19). Although the sensitivity of the assay remains high (83%), with all known or predicted human carcinogens, except phenacetin, identi ed as positive in the SHE assay, the speci city of the assay is low (15%), with only mannitol and sul soxazole correctly identi ed from the 13 compounds predicted to be human noncarcinogens. The low speci city of the assay for the detection of human carcinogens, however, may be skewed by the large percentage of compounds included in this test set that are known rodent carcinogens, but predicted not to be human carcinogens based on knowledge of the mechanism of the drugs. For example, peroxisome proliferators (clo brate, DEHP, and WY-14643) are known to induce rodent tumors by a rodent-speci c process and were positive as would be expected for a rodent-based assay.
In this set of testing, several compounds were assayed in more than 1 laboratory. D-mannitol was analyzed by all 3 participating laboratories and in all cases was negative when tested up to the maximum dose of 5 mg/ml. Phenobarbitol was also assessed across laboratories with similar results and dose concentrations evaluated. Interestingly, a similar response was observed for all testing with phenobarbitol, with several dose concentrations causing a statistically signi cant increase in MTF, but higher concentrations failing to produce a response. In addition, WY-14643, diethylstilbestrol, and estradiol were tested in more than 1 laboratory with similar results observed. Therefore, although rigorous interlaboratory studies have not been conducted, it is evident that different SHE cell preparations used in different laboratories can generate comparable data in the SHE assay.
These data suggest that the SHE assay is a valuable predictor of rodent carcinogenesis, and possesses the ability to differentiate between subtle chemical or mechanistic differences leading to different carcinogenic outcomes. The assay also appears to have the capacity to identify human carcinogens, but with the limitation of low speci city and therefore a high false-positive rate. The lack of speci city for human carcinogens is likely a direct result of the rodent source of cells, which must be factored into any analysis of the assay's utility. Therefore, the SHE assay can be utilized to predict potential carcinogenic outcome and, with additional mechanistic information to interpret potential species differences, can be used to aid in assessing the human carcinogenic risk of exposure to chemicals.
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